We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+28.71%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.61B
AUM Growth
+$255M
Cap. Flow
+$47.3M
Cap. Flow %
1.31%
Top 10 Hldgs %
49.77%
Holding
131
New
18
Increased
36
Reduced
18
Closed
31

Top Buys

Rank Stock Value
1
MANE
Veradermics Inc
MANE
+$75.9M
2
CYTK icon
Cytokinetics
CYTK
+$39M
3
OLMA icon
Olema Pharmaceuticals
OLMA
+$32.4M
4
ERAS icon
Erasca
ERAS
+$29.4M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$23.3M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$76.1M
2
APLS
Apellis Pharmaceuticals
APLS
+$64.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$50.3M
4
RAPT
RAPT Therapeutics
RAPT
+$46.6M
5
ZYME icon
Zymeworks
ZYME
+$44.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.63%
2 Technology 3.69%
3 Communication Services 1.71%
4 Consumer Discretionary 0.77%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADBE icon
101
Adobe
ADBE
$94.5B
– –
-12,051
Closed -$4.22M
APLS
102
DELISTED
Apellis Pharmaceuticals
APLS
– –
-2,578,396
Closed -$64.8M
ARM icon
103
Arm
ARM
$285B
– –
-21,500
Closed -$2.35M
ASND icon
104
Ascendis Pharma A/S
ASND
$16.6B
– –
-235,862
Closed -$50.3M
BDTX icon
105
Black Diamond Therapeutics
BDTX
$99.1M
– –
-1,046,517
Closed -$2.54M
BNTC icon
106
Benitec Biopharma
BNTC
$398M
– –
-775,000
Closed -$10.4M
CMPS
107
Compass Pathways
CMPS
$1.52B
– –
-1,000,000
Closed -$6.9M
CRBU icon
108
Caribou Biosciences
CRBU
$157M
– –
-105,347
Closed -$168K
CRM icon
109
Salesforce
CRM
$142B
– –
-26,100
Closed -$6.91M
CYCN icon
110
Cyclerion Therapeutics
CYCN
$15.2M
– –
-115,603
Closed -$147K
EDU icon
111
New Oriental
EDU
$7.94B
– –
-62,000
Closed -$3.41M
GBIO
112
DELISTED
Generation Bio
GBIO
– –
-201,419
Closed -$1.14M
IHS icon
113
IHS Holding
IHS
$2.77B
– –
-2,357,520
Closed -$17.6M
LXEO icon
114
Lexeo Therapeutics
LXEO
$352M
– –
-720,622
Closed -$7.16M
META icon
115
Meta Platforms (Facebook)
META
$1.51T
– –
-7,169
Closed -$4.73M
MLYS icon
116
Mineralys Therapeutics
MLYS
$2.4B
– –
-699,999
Closed -$25.4M
PANW icon
117
Palo Alto Networks
PANW
$259B
– –
-11,450
Closed -$2.11M
PEPG icon
118
PepGen
PEPG
$131M
– –
-700,000
Closed -$4.56M
QCOM icon
119
Qualcomm
QCOM
$179B
– –
-14,000
Closed -$2.39M
RAPT
120
DELISTED
RAPT Therapeutics
RAPT
– –
-1,375,000
Closed -$46.6M
SGMT icon
121
Sagimet Biosciences
SGMT
$460M
– –
-724,771
Closed -$4.29M
SVRA icon
122
Savara
SVRA
$1.11B
– –
-1,000,000
Closed -$6.03M
TIL icon
123
Instil Bio
TIL
$48.5M
– –
-203,933
Closed -$2.24M
VRNS icon
124
Varonis Systems
VRNS
$5.36B
– –
-37,500
Closed -$1.23M
XFOR icon
125
X4 Pharmaceuticals
XFOR
$371M
– –
-1,500,000
Closed -$6M
2 3 4
5
6

Similar funds

U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $3.61B AUM 24.09% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $3.63B AUM 17.91% 1-Year Est. Return

Siren LLC's Q1 2026 Portfolio in Review

As of Q1 2026, Siren LLC held 131 positions worth $3.61B, up 7.6% from $3.35B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Siren LLC's Q1 2026 filing shows 18 new, 36 increased, 18 reduced and 31 closed positions. Its largest new stake was Veradermics Inc: 1,505,374 shares worth $95.1M. The largest sale was Centessa Pharmaceuticals, an estimated $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q1 2026 buy was Veradermics Inc: 1,505,374 shares worth $95.1M.
  • Siren LLC added most to Olema Pharmaceuticals in Q1 2026, an estimated $32.4M increase.
  • Siren LLC's biggest Q1 2026 reduction was Centessa Pharmaceuticals, cutting an estimated $76.1M.
  • Siren LLC fully exited Apellis Pharmaceuticals in Q1 2026, selling an estimated $64.8M.
  • Siren LLC's ten largest holdings make up 50% of its $3.61B portfolio in Q1 2026.
  • Siren LLC opened 18 new positions and closed 31 in Q1 2026.
  • Siren LLC's portfolio value rose 7.6% quarter-over-quarter to $3.61B.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.